Synopsis
Synopsis
0
JDMF
0
VMF
0
South Africa
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (2s)-2-((4r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
2. 1-pyrrolidineacetamide, Alpha-ethyl-2-oxo-4-propyl-, (alphas,4r)-
3. 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
4. Briviact
5. Ucb 34714
6. Ucb-34714
7. Ucb34714
1. 357336-20-0
2. Briviact
3. Ucb-34714
4. Ucb 34714
5. Ucb34714
6. 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
7. (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
8. (2s)-2-((4r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
9. U863jgg2ia
10. Rikelta
11. Brivaracetam [usan:inn]
12. Unii-u863jgg2ia
13. Compound 83alpha
14. 1-pyrrolidineacetamide, Alpha-ethyl-2-oxo-4-propyl-, (alphas,4r)-
15. Brivaracetam 97%
16. Briviact (tn)
17. Brivaracetam [mi]
18. Brivaracetam [inn]
19. Brivaracetam [jan]
20. Brivaracetam [usan]
21. Brivaracetam [mart.]
22. Brivaracetam [who-dd]
23. Schembl122081
24. Brivaracetam (jan/usan/inn)
25. Chembl607400
26. Gtpl9041
27. Dtxsid00905081
28. Chebi:133013
29. Brivaracetam [orange Book]
30. Ex-a2748
31. Zinc3979899
32. Bdbm50422531
33. Mfcd25976668
34. Akos027324306
35. Ccg-266666
36. Cs-3418
37. Db05541
38. Ncgc00390779-02
39. Ac-29289
40. As-35277
41. Bb161996
42. Hy-14449
43. D08879
44. Q408099
45. (s)-2-((r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
46. (2s)-2-((4r)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide
47. (2s)-2-((4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl) Butanamide
48. 1-pyrrolidineacetamide, .alpha.-ethyl-2-oxo-4-propyl (.alpha.s,4r)-
| Molecular Weight | 212.29 g/mol |
|---|---|
| Molecular Formula | C11H20N2O2 |
| XLogP3 | 1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 212.152477885 g/mol |
| Monoisotopic Mass | 212.152477885 g/mol |
| Topological Polar Surface Area | 63.4 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 253 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
FDA Label
Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Treatment of epilepsy with partial-onset seizures, Treatment of neonatal seizures
Treatment of neonatal seizures, Treatment of paediatric epilepsy syndromes
Treatment of epilepsy with partial-onset seizures
Brivaracetam binds SV2A with high affinity. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam is also known to inhibit Na+ channels which may also contribute to its anti-epileptogenic action.
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
N03AX23
N03AX23
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX23 - Brivaracetam
Absorption
Nearly 100% oral bioavailability.
Route of Elimination
\>95% excreted in urine with <10% of the parent compound unchanged. <1% excreted in feces.
Volume of Distribution
0.5L/kg.
Clearance
CL/F of 0.7-1.07 mL/min kg. Clearance is primarily metabolic with less than 10% of the parent drug excreted unchanged.
Primarily metabolized by hydrolysis of the acetamide moeity to form a carboxylic acid metabolite. Another metabolite is created via oxidation of the propyl side chain by CYP2C8 as well as CYP3A4, CYP2C19, and CYP2B6. Some conjugation with glucuronic acid and taurine account for a small amount of metabolism.
7-8h.
The precise mechanism of brivaracetam's anti-epileptogenic activity is unknown.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36655
Submission : 2022-01-08
Status : Active
Type : II
Date of Issue : 2025-08-05
Valid Till : 2028-06-25
Written Confirmation Number : WC-0054
Address of the Firm :
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-10-05
Registration Number : Su434-60-ND
Manufacturer Name : Ami Lifesciences Private Limited
Manufacturer Address : Block No. 82/B, ECP Road At & Post. Karakhadi, Tal-Padra, City : Karakhadi-391450, Dist : Vadodara, Gujarat State, India
| Available Reg Filing : ASMF |
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41491
Submission : 2025-03-31
Status : Active
Type : II
NDC Package Code : 52076-6268
Start Marketing Date : 2020-12-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Delivering Quality APIs, Drug Intermediates, and Specialty Chemicals to Over 50 Countries Across the Globe.
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2021-02-09
Registration Number : Wed 21-19-ND
Manufacturer Name : Honour Lab Limited Unit III
Manufacturer Address : Plot No.4, Hetero Infrastructure SEZ Ltd, N.Narasapuram Village, Nakkapalli Mandal, Anakapalli District - 531 081, Andhra Pradesh, India
| Available Reg Filing : ASMF, CN |
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-03-23
Pay. Date : 2020-02-18
DMF Number : 34402
Submission : 2019-12-09
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2025

Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsy, Absence.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsy, Absence.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brecita (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Neurology Brand Name: Brecita
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 01, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brecita (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
Product Name : Brecita
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 01, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Seizures.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: GX Pharma Technology
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : GX Pharma Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustain...
Details : Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Seizures.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 18, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Positive topline results from a Phase 3 study investigating the efficacy and safety of adjunctive brivaracetam in participants across Asia (≥16 to 80 years of age) with partial seizures with or without secondary generalization.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Neurology Brand Name: Brecita
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
UCB Announces Positive Preliminary Results For Major Brivaracetam (Briviact[®]) Study In Asia
Details : Positive topline results from a Phase 3 study investigating the efficacy and safety of adjunctive brivaracetam in participants across Asia (≥16 to 80 years of age) with partial seizures with or without secondary generalization.
Product Name : Brecita
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 10, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 07, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BRIVIACT (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Neurology Brand Name: Brecita
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRIVIACT (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
Product Name : Brecita
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 01, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
With these positive CHMP opinions, BRIVIACT® (brivaracetam) and VIMPAT® (lacosamide) will provide young patients and their caregivers with additional treatment options for POS with or without secondary generalization.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Neurology Brand Name: Brecita
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 02, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT...
Details : With these positive CHMP opinions, BRIVIACT® (brivaracetam) and VIMPAT® (lacosamide) will provide young patients and their caregivers with additional treatment options for POS with or without secondary generalization.
Product Name : Brecita
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 02, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsy, Absence.
Lead Product(s): Brivaracetam,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 05, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brivaracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsy, Absence.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 05, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : TABLET; ORAL
Dosage Strength : 25mg
Approval Date :
Application Number : 214831
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : TABLET; ORAL
Dosage Strength : 50mg
Approval Date :
Application Number : 214831
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : TABLET; ORAL
Dosage Strength : 75mg
Approval Date :
Application Number : 214831
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : SOLUTION;ORAL
Dosage Strength : 10MG/ML
Approval Date :
Application Number : 218494
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2022-12-20
Application Number : 214918
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : TABLET;ORAL
Dosage Strength : 25MG
Approval Date : 2022-12-20
Application Number : 214918
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date : 2022-12-20
Application Number : 214918
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 50MG/5ML (10MG/ML)
Approval Date :
Application Number : 214924
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : BRIVIACT
Dosage Form : SOLUTION;ORAL
Dosage Strength : 10MG/ML
Approval Date : 2016-05-12
Application Number : 205838
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : BRIVARACETAM
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Approval Date : 2022-10-03
Application Number : 214501
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
70
PharmaCompass offers a list of Brivaracetam API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Brivaracetam manufacturer or Brivaracetam supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Brivaracetam manufacturer or Brivaracetam supplier.
PharmaCompass also assists you with knowing the Brivaracetam API Price utilized in the formulation of products. Brivaracetam API Price is not always fixed or binding as the Brivaracetam Price is obtained through a variety of data sources. The Brivaracetam Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Briviact manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Briviact, including repackagers and relabelers. The FDA regulates Briviact manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Briviact API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Briviact manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Briviact supplier is an individual or a company that provides Briviact active pharmaceutical ingredient (API) or Briviact finished formulations upon request. The Briviact suppliers may include Briviact API manufacturers, exporters, distributors and traders.
click here to find a list of Briviact suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Briviact DMF (Drug Master File) is a document detailing the whole manufacturing process of Briviact active pharmaceutical ingredient (API) in detail. Different forms of Briviact DMFs exist exist since differing nations have different regulations, such as Briviact USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Briviact DMF submitted to regulatory agencies in the US is known as a USDMF. Briviact USDMF includes data on Briviact's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Briviact USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Briviact suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Briviact Drug Master File in Korea (Briviact KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Briviact. The MFDS reviews the Briviact KDMF as part of the drug registration process and uses the information provided in the Briviact KDMF to evaluate the safety and efficacy of the drug.
After submitting a Briviact KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Briviact API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Briviact suppliers with KDMF on PharmaCompass.
A Briviact CEP of the European Pharmacopoeia monograph is often referred to as a Briviact Certificate of Suitability (COS). The purpose of a Briviact CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Briviact EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Briviact to their clients by showing that a Briviact CEP has been issued for it. The manufacturer submits a Briviact CEP (COS) as part of the market authorization procedure, and it takes on the role of a Briviact CEP holder for the record. Additionally, the data presented in the Briviact CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Briviact DMF.
A Briviact CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Briviact CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Briviact suppliers with CEP (COS) on PharmaCompass.
A Briviact written confirmation (Briviact WC) is an official document issued by a regulatory agency to a Briviact manufacturer, verifying that the manufacturing facility of a Briviact active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Briviact APIs or Briviact finished pharmaceutical products to another nation, regulatory agencies frequently require a Briviact WC (written confirmation) as part of the regulatory process.
click here to find a list of Briviact suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Briviact as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Briviact API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Briviact as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Briviact and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Briviact NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Briviact suppliers with NDC on PharmaCompass.
Briviact Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Briviact GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Briviact GMP manufacturer or Briviact GMP API supplier for your needs.
A Briviact CoA (Certificate of Analysis) is a formal document that attests to Briviact's compliance with Briviact specifications and serves as a tool for batch-level quality control.
Briviact CoA mostly includes findings from lab analyses of a specific batch. For each Briviact CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Briviact may be tested according to a variety of international standards, such as European Pharmacopoeia (Briviact EP), Briviact JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Briviact USP).